| Name | Title | Contact Details |
|---|
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
UDG Healthcare plc, formerly United Drug, is a Dublin-based international company and partner to the healthcare industry, providing clinical, commercial, communication and packaging services.
Pharmessen Scientific, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CompleGen is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cardiology Associates of Alabama offers vascular care and heart treatments including structural heart, interventional procedures, pediatric cardiology, heart rhythm disorders, and congestive heart failure.